- Home
- NLSP vs BDRX Comparison
NLSP vs BDRX Comparison
Compare NLSP & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NLSP
- BDRX
- Stock Information
- Founded
- NLSP 2015
- BDRX 2000
- Country
- NLSP Switzerland
- BDRX United Kingdom
- Employees
- NLSP N/A
- BDRX N/A
- Industry
- NLSP Biotechnology: Pharmaceutical Preparations
- BDRX Biotechnology: Pharmaceutical Preparations
- Sector
- NLSP Health Care
- BDRX Health Care
- Exchange
- NLSP Nasdaq
- BDRX Nasdaq
- Market Cap
- NLSP 12.4M
- BDRX 3.8M
- IPO Year
- NLSP 2021
- BDRX N/A
- Fundamental
- Price
- NLSP $2.03
- BDRX $6.52
- Analyst Decision
- NLSP
- BDRX
- Analyst Count
- NLSP 0
- BDRX 0
- Target Price
- NLSP N/A
- BDRX N/A
- AVG Volume (30 Days)
- NLSP 200.9K
- BDRX 52.6K
- Earning Date
- NLSP 10-17-2025
- BDRX 09-23-2025
- Dividend Yield
- NLSP N/A
- BDRX N/A
- EPS Growth
- NLSP N/A
- BDRX N/A
- EPS
- NLSP N/A
- BDRX N/A
- Revenue
- NLSP N/A
- BDRX N/A
- Revenue This Year
- NLSP N/A
- BDRX N/A
- Revenue Next Year
- NLSP N/A
- BDRX N/A
- P/E Ratio
- NLSP N/A
- BDRX N/A
- Revenue Growth
- NLSP N/A
- BDRX N/A
- 52 Week Low
- NLSP $1.30
- BDRX $5.00
- 52 Week High
- NLSP $6.97
- BDRX $108.90
- Technical
- Relative Strength Index (RSI)
- NLSP 43.44
- BDRX 53.49
- Support Level
- NLSP $1.88
- BDRX $5.81
- Resistance Level
- NLSP $2.29
- BDRX $6.47
- Average True Range (ATR)
- NLSP 0.12
- BDRX 0.50
- MACD
- NLSP -0.01
- BDRX 0.18
- Stochastic Oscillator
- NLSP 36.59
- BDRX 82.40
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.